On the 10 Nov Bluchiip released the announcement RE Bluechiip...

On the 10 Nov Bluchiip released the announcement RE Bluechiip signs international agreement for technology integration
In this announcement it mentions the following:
"SIAD Group (SIAD) ITALY and Bluechiip have entered into a test and evaluation project for SIAD to integrate the Bluechiip cryotag into SIAD’s cryobags which are used to store cord blood and other biological products. On the successful completion of this test and evaluation after 3 months, both companies will negotiate the commercialisation of the integrated product."

Well if my maths serves me correctly we are coming up to the end of that three month period.

Perhaps this may be raised and further details provided in the half yearly report due around 28 Feb or even better beforehand.

Similarly:
1. Glory Biotech Corp the org. in Korea who signed an agreement late OCT last year have had some time to bed down processes. Perhaps early days yet...
2. Distribution Agreement with LBD Life Sciences in China Feb 2014 followed by Bluechiip system installed at the Shanghai Outdo Biotech Co., Ltd, a leading biobank in China sometime around July 2014. You would expect that some real development has occurred since that time.
3. Distribution Agreement with Biospensa Resources Malaysia was signed way back in Feb 2014. Seems fair that things would have progressed.
4. Genomics and Clinical Laboratory, North Carolina, USA, Australian Synchrotron, Australia and Southern Health, Victoria, Australia all made sales in April 2014. Further progress should be of interest.

The distribution agreement for Korea had 330k minimum ordering obligations, the other agreements didn't detail min obligations but expect there would have been some agreement for this; unless of course Bluechiip management got wiser at the negotiating table

In the H/Yearly report we should see how much R&D tax concession was received; that would help cash flow.

So there should be plenty of potential for news about progress and how the commercialisation strategy is panning out.
At least in the next few weeks some questions will be answered.

Fargo